新型冠狀病毒肺炎（COVID-19）患者尤其危重癥患者，疾病后常伴有D-二聚體升高，易誘發(fā)或者加重缺血性腦卒中的發(fā)生。而兩種疾病在病史初期均存在頭痛、嘔吐、發(fā)熱、呼吸急促等相似癥狀，容易造成誤診、漏診，且相互影響，導致病程延長。針對COVID-19患者，需積極盡早采取抗毒病治療，合并腦卒中的患者，需密切監(jiān)測D-二聚體的指標變化，根據其指標給予患者適宜的抗栓治療，一旦D-二聚體升高，建議立即啟動抗凝措施，同時需控制患者血壓血脂等高危因素。結合腦卒中相關用藥研究，探討COVID-19合并腦卒中這類高危人群的合理用藥策略與藥學監(jiān)護，為此類患者提供合理用藥參考。

Coronavirus disease 2019 (COVID-19) patients are particularly critically ill, often accompanied by D-djurogen elevation, easy to induce or aggravate the occurrence of ischemic stroke. Both diseases have similar symptoms such as headache, vomiting, fever and shortness of breath in the early stages of their medical history, which can easily lead to misdiagnosis, missed diagnosis, and mutual influence, resulting in prolonged course of illness. For patients with COVID-19, anti-venom treatment should be actively taken as soon as possible, combined with stroke patients, the indicator change of D-diamer should be closely monitored, according to its indicators to give patients appropriate anti-thrombosis treatment, once the D-diamer rises, it is recommended to start anticoagulant immediately, while controlling the patient's blood pressure lipids and other high-risk factors. In this paper, combined with the research on stroke-related drug use, this paper discusses the rational drug use strategy and pharmacological care of high-risk groups such as COVID-19 combined with stroke, and provides reasonable drug use reference for such patients.

國家重點研發(fā)計劃項目（2017YFC0909904）